Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer

Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is used to profile the circulating DNA of ALTER0303 (evaluating NSCLC clinical antitumor efficacy through anlo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Adv Sci (Weinh)
Main Authors: Lu, Jun, Zhong, Hua, Wu, Jun, Chu, Tianqing, Zhang, Lele, Li, Hua, Wang, Qiming, Li, Rong, Zhao, Yizhuo, Gu, Aiqin, Wang, Huimin, Shi, Chunlei, Xiong, Liwen, Zhang, Xueyan, Zhang, Wei, Lou, Yuqing, Yan, Bo, Dong, Yu, Zhang, Yanwei, Li, Baolan, Zhang, Li, Zhao, Xiaodong, Li, Kai, Han, Baohui
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Full Papers
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774020/
https://ncbi.nlm.nih.gov/pubmed/31592412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/advs.201900721
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki